|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy显示文摘 | Khalid Abozguia Perry Elliott William McKenna Thanh Trung Phan Ganesh Nallur-Shivu Ibrar Ahmed Abdul R. Maher Kulvinder Kaur Jenny Taylor Anke Henning Houman Ashrafian Hugh Watkins Michael Frenneaux | 2010 | Circulation2010，，16： | 2 |
| 2 | Evaluation of glass and basalt fiber reinforcements for polymer composite pressure piping显示文摘 | Pierre Mertiny Kulvinder Juss Mohab M | 2009 | Adv Compos Mater Eng2009，131，： | 1 |
| 3 | Karyotype and C-banding patterns of mitotic chromosomes in diploid bromegrass(Bromus riparius Rehm)显示文摘 | Metin Tuna Kulvinder S Gill Kenneth P Vogel | 2000 | J of Range Management2000，74，： | 1 |
| 4 | Comparisons of RFLP and PCR-based markers to detect polymorphism between wheat cultivars显示文摘 | Mohammad Maroof Shah Yang Yen Kulvinder S. Gill P. Stephen Baenziger | 2000 | Euphytica2000，，2： | 1 |
| 5 | Identification and analysis of expressed resistance gene sequences in wheat 显示文摘 | Muharrem D Kulvinder S G | 2004 | Plant Molecular Biology2004，48，： | 1 |
| 6 | Plain radiographic diagnosis of mobile esophageal polyp- Now you see me, now you don' t显示文摘 | Kulvinder Singh Saru Singh Kunwarpal Singh | 2014 | Radiography2014，20，03： | 1 |
| 7 | Microproteinuria predicts the severity of systemic effects of reperfusion injury following infrarenal aortic aneurysm surgery显示文摘 | Frank C. T. Smith BSc FRCS Peter Gosling BSc PhD MRC Path Kulvinder Sanghera BSc Marcus A. Green FRCS Ian S. Paterson MD FRCS Senior Lecturer Clifford P. Shearman BSc MD FRCS | 1994 | Annals of Vascular Surgery1994，，1： | 1 |
| 8 | Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy显示文摘 | Khalid Abozguia Perry Elliott William McKenna Thanh Trung Phan Ganesh Nallur-Shivu Ibrar Ahmed Abdul R. Maher Kulvinder Kaur Jenny Taylor Anke Henning Houman Ashrafian Hugh Watkins Michael Frenneaux | 2010 | Circulation2010，，16： | 1 |
| 9 | An Update on Management of Nonalcoholic Fatty Liver Disease&Nonalcoholic Steatohepapititis is the Time Ripe for Achieving Resolution of NAFLD&NASH Soon显示文摘We earlier reviewed how obesity has assumed an endemic/pandemic proportions that has resulted in escalating incidence and prevalence of associated escalating worldwide incidence of Metabolic Syndrome(MetS)with non alcoholic fatty liver disease(NAFLD),that is correlated with enhanced morbidity.Later we tried to detail how probiotics,L-Carnitine(LC),Nicotinamide Ribose(NR)Combination,along with Apical Sodium Dependent Bile Acids Transporter(ASBT)or Volixibat and Silybin,Vitamin D,Allyl Isothiocyanate(AITC),might aid in treating and understand the etiopathogenesis of NAFLD.The prevalence of NAFLD all over the world is approximately 25%,with that of non alcoholic steatohepapititis(NASH),varying from 1.5%=6.45%.Particularly NASH,specifically the ones associated with fibrosis possess a greater chance of generation of side effects that include progression to cirrhosis as well as liver-associated mortality.Despite an improvement was observed with vitamin E,Pioglitazone.liraglutide in histological appearance in liver randomized controlled clinical trials(RCT),at present no drugs exists that have received FDI approval for NASH.The aim of this review was to update the newer drugs getting evaluated,undergoing phase 2-3 trials.Currently there are Obeticholic acid,elafibranor,cenicriviroc,resmetriom,in addition to aramchol,that are the five agents that are getting analysed in big,histology dependent phase 3 trials.Hopefully within another 2-4 years,newer,efficacious drugs will be available for the therapy of NASH.Besides that a lot of phase 2 trials are continuing for different drugs.Further depending on outcomes of phase 2-3 trials,combination treatments are getting evaluated.For future therapeutic approaches would be made up of variations in NASH phenotypes,besides personalized approaches based on various NASH phenotypes in addition to response of every single patient.Further recently there were reports of utilization of curcumin with nonselective beta blocker for regression from cirrhosis(reviewed by us).Hopefully once there are approved therapies for NAFLD/NASH,we can work in that direction. | Kulvinder Kochar Kaur Gautam Allahbadia Mandeep Singh | 2021 | Journal of Endocrinology Research2021，3，2： | 1 |
| 10 | Arsenic Removal from Groundwater Using Iron Pyrite:Influence Factors and Removal Mechanism显示文摘Iron pyrite has been reported as a kind of potential material for arsenic(As)removal from the groundwater because it exhibits a strong attraction in groundwater for both arsenite and arsenate species.In this study,batch adsorption experiments were carried out to determine the optimum conditions for As adsorption by the iron pyrite adsorbent,including the initial concentration,adsorbent dosage ratio,pH,temperature and stirring rate.Precisely characterization methods were employed to identify the mechanism of As removal.Maximum removal efficiency for As(Ⅲ)was observed 93%at pH=7,and for As(Ⅴ)was 95%observed at pH=5.Langmuir model resulted in the maximum adsorption capacity(q_(m))for As(Ⅲ)and As(Ⅴ)were 571.7 and 671.1μg/g,respectively,as well as the experiments were found to be favorable as separation factor R_(L)<1.The value of“n”2.68 and 2.47 for As(Ⅲ)and As(Ⅴ)obtained by Freundlich model(n>1)indicates favorable adsorption.The pseudo-first and second-order kinetic models also fitted well.The addition of oxalate on the adsorbent surface plays an important role for the recycling of Fe(Ⅱ)/Fe(Ⅲ)to minimize the arsenic concentration.Specific surface area,ion exchange mechanism and structure of adsorbent confirmed that addition of oxalate could enhance the surface area of adsorbent. | Muhammad Yousuf Jat Baloch Chunli Su Shakeel Ahmed Talpur Javed Iqbal Kulvinder Bajwa | 2023 | Journal of Earth Science2023，34，3： | 0 |
| 11 | The Association of Non Viral Liver Diseases from NAFLD to NASH to HCC with the Pandemic of Obesity,Type 2 Diabetes,or Diabesity&Metabolic Syndrome Etiopathogenetic Correlation along with Utilization for Diagnostic&Therapeutic Purposes-A Systematic Review显示文摘Earlier we have been reviewing the etiopathogenesis(EP)of obesity,type2 Diabetes mellitus(T2DM),Metabolic Syndrome(MetS),Non Alcoholic Fatty Acid Liver Disease(NAFLD)non alcoholic steatohepapititis(NASH),along with its propagation to Hepatocellular carcinoma(HCC)in addition to their therapies exhaustively.T2DM continues to be a major health issue with reaching epidemic to pandemic proportions.Liver disease includes a spectrum of liver injury varying from isolated steatosis known as Non Alcoholic Fatty Acid Liver Disease(NAFLD)to HCC.Clinically it has been observed that the coexistence of NAFLD as well as T2DM is prevalent.T2DM aids in the biological events that results in escalation of robustness of NAFLD that constitutes the primary etiology of chronic liver diseases.In the past 2 decades the incidence of nonviral NAFLD/NASH,obtained HCC has been escalating at a fast pace.In view of no appropriate agents for therapy of NAFLD/NASH,a thiazolidenedione group of drug pioglitazone used for T2DM therapy is utilized occasionally.Thus here we conducted a systematic review utilizing search engine pubmed,google scholar;web of science;embase;Cochrane review libraryutilizingtheMeSHterms like T2DM;MetS;NAFLD;NASH;HCC;WAT;BAT;VisceralAT;Obesity;BMI;Adipocytokines;adiponectin;leptin;resistin;visfatin;irisin;Hepatokines;angiopoietin like protein 2;hepatosscin;retinol binding protein 4;treatment like pioglitazone;liraglutide;elafibranor CVC(cerviciroc);obeticholic acid;aramchol;selonosertib;simtuzumab;Oxidative stress(OS);insulin resistance(IR)from 1980’s to 2021 till date.We found a total of 1050 articles out of which we selected 236 articles for this review.No meta-analysis was done.Hence diagnosis avoidance in addition to treatment of the generation as well as propagation of NAFLD/NASH are significant areas needing tackling.Thus here we have summarized the EP of NAFLD/NASH,as well as NAFLD/NASH,obtained HCC along with the present advantageous therapies under trial,for NAFLD/NASH.Moreover how adipocyte obtained adipokines along with liver obtained hepatokines might work as both diagnostic in addition to therapeutic targets from NAFLD to HCC. | Kulvinder Kochar Kaur Gautam Allahbadia Mandeep Singh | 2021 | Journal of Endocrinology Research2021，3，2： | 0 |
| 12 | Therapeutic role of Ricinus communis L. and its bioactive compounds in disease prevention and treatment显示文摘Ricinus communis L.(R. communis), commonly known as castor oil plant, is used as a traditional natural remedy or folkloric herb for the control and treatment of a wide range of diseases around the globe. Various studies have revealed the presence of diverse phytochemicals such as alkaloids.flavonoids, terpenes, saponins,phenolic compounds such as kaempferol, gallic acid, ricin, rutin, lupeol, ricinoleic acid, pinene, thujone and gentisic acid.These phytochemicals have been responsible for pharmacological and therapeutic effects,including anticancer, antimicrobial, insecticidal, antioxidant, anti-diabetic, antinociceptive,anti-inflammatory. bone regenerative, analgesic, and anticonvulsant activity. R. communis harbours phytochemicals which have been shown to target peroxisome proliferator activated receptor(PPAR), nuclear factor NF-κ-B, cytochrome p450, P38 mitogen-activated protein kinases kinase(p38 MAPK), tumor protein P53, B-cell lymphoma-extra-large(Bcl-xL) and vascular endothelial growth factor receptor-2(VEGFR-2). Considering its wide variety of phytochemicals, its pharmacological activity and the subsequent clinical trials, R. communis could be a good candidate for discovering novel complementary drugs. Further experimental and advanced clinical studies are required to explore the pharmaceutical, beneficial therapeutic and safety prospects of R. communis with its phytochemicals as a herbal and complementary medicine for combating various diseases and disorders. | Waseem Mohammed Abdul Nahid H.Hajrah Jamal S.M.Sabir Saleh M.Al-Garni Meshaal J.Sabir Saleh A.Kabli Kulvinder Singh Saini Roop Singh Bora | 2018 | Asian Pacific Journal of Tropical Medicine2018，11，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员